Dan Holms, MD. talks about the current state of clinical proteomics
Dr. Holms explains how clinical proteomics can impact patient care
Professor Akhilesh Pandey from Johns Hopkins about clinical proteomics
Professor Akhilesh Pandey, M.D., Ph.D. talks about the current situation for clinical proteomics and what is looming on the horizon.
Dr. Thomas Conrads about clinical proteomics and APOLLO
Dr. Conrads explains how clinical proteomics can improve cancer treatment with early detection, molecular diagnosis and increased precision.
Sample prep – the final frontier in biomarker testing
Biomarker tests have become an important tool in clinical diagnostics. The PSA test evaluates the risk for prostate cancer, and inflammatory and myocardial panels save lives when performed fast enough. Still biomarkers, especially protein biomarkers, are not yet used to their full potential. While novel approaches employ mass spectrometry instead of immunoassay detection, one bottleneck remains: the need for robust, fast, and efficient sample preparation.
